Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Solasia Invests in Sweden’s Isofol as Colorectal Cancer Trials Resume
July 14, 2025
- All Three PPI Switch OTCs Approved following MHLW Panel OK
July 14, 2025
- More Firms Signal Interest in Meiji-Daito Consortium to Revamp Generic Production
July 14, 2025
- Espha President Signals Move Toward Novel Drug Development amid Group Shift
July 11, 2025
- Izervay US Sales Reach 15.9 Billion Yen in April-June: Astellas
July 11, 2025
- Taiho’s DMD Drug TAS-205 Falls Short in PIII Trial
July 9, 2025
- JCR Licenses Gene Therapy Platform to Alexion
July 9, 2025
- Japan’s CAR-T Market Set to Double by 2030, Hitting 39 Billion Yen: Fuji Keizai
July 9, 2025
- Japan Ethical Drug Sales Up 0.5% in May: Crecon
July 9, 2025
- ASKA Targets 30% Overseas Sales Ratio through Southeast Asia Expansion: New President
July 9, 2025
- Fujifilm to Offer Small-Batch CDMO Services for Investigational mRNA Drugs from 2026
July 8, 2025
- Chugai, Gero Ink Joint Research on Aging-Related Diseases
July 8, 2025
- Nxera Earns US$4.8 Million Milestone as Centessa’s OX2R Drug Advances
July 7, 2025
- Keytruda Tops Japan Drug Ranking for 21st Month: Encise
July 7, 2025
- Taking on Solid Tumors - 7: Astellas Aims for Global Lead in CLDN18.2 TCEs, Building on Success with Vyloy
July 3, 2025
- Nippon Shinyaku Strikes Research Pact with Boston Children’s Hospital
July 2, 2025
- BeiGene Japan Rebrands as BeOne, Debuts PD-1 Inhibitor Tevimbra
July 2, 2025
- ASKA Moves to Counter Dalton Investments’ Rapid Share Purchase
July 2, 2025
- Mitsubishi Tanabe to Rebrand as Tanabe Pharma after Bain Takeover
July 2, 2025
- Tavalisse Now Available in South Korea for Chronic ITP: Kissei
July 2, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…